35 related articles for article (PubMed ID: 38488682)
1. ITGB2 as a prognostic indicator and a predictive marker for immunotherapy in gliomas.
Xu H; Zhang A; Han X; Li Y; Zhang Z; Song L; Wang W; Lou M
Cancer Immunol Immunother; 2022 Mar; 71(3):645-660. PubMed ID: 34313821
[TBL] [Abstract][Full Text] [Related]
2. Correlation between ITGB2 expression and clinical characterization of glioma and the prognostic significance of its methylation in low-grade glioma(LGG).
Liu H; Wang J; Luo T; Zhen Z; Liu L; Zheng Y; Zhang C; Hu X
Front Endocrinol (Lausanne); 2022; 13():1106120. PubMed ID: 36714574
[TBL] [Abstract][Full Text] [Related]
3. Immune Infiltrating Cells-Derived Risk Signature Based on Large-scale Analysis Defines Immune Landscape and Predicts Immunotherapy Responses in Glioma Tumor Microenvironment.
Zhang N; Zhang H; Wang Z; Dai Z; Zhang X; Cheng Q; Liu Z
Front Immunol; 2021; 12():691811. PubMed ID: 34489938
[TBL] [Abstract][Full Text] [Related]
4. A novel immunogenic cell death-related gene risk signature can identify biomarkers of gliomas and predict the immunotherapeutic response.
Tang X; Wang K; Yang J; Wang Y; Yan Z
Am J Cancer Res; 2024; 14(1):324-343. PubMed ID: 38323285
[TBL] [Abstract][Full Text] [Related]
5. PDIA5 is Correlated With Immune Infiltration and Predicts Poor Prognosis in Gliomas.
Zhang H; He J; Dai Z; Wang Z; Liang X; He F; Xia Z; Feng S; Cao H; Zhang L; Cheng Q
Front Immunol; 2021; 12():628966. PubMed ID: 33664747
[TBL] [Abstract][Full Text] [Related]
6. Exploring the impact of ITGB2 on glioma progression and treatment: Insights from non-apoptotic cell death and immunotherapy.
Zhuang J; Miao C; Liu C; Zeng B; Hu L; Peng J; Xia Y; Chen Z
Environ Toxicol; 2024 Mar; ():. PubMed ID: 38488682
[TBL] [Abstract][Full Text] [Related]
7. Unveiling the landscape of cytokine research in glioma immunotherapy: a scientometrics analysis.
Zhang H; Chen Y; Jiang X; Gu Q; Yao J; Wang X; Wu J
Front Pharmacol; 2023; 14():1333124. PubMed ID: 38259287
[No Abstract] [Full Text] [Related]
8. Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma.
Yang L; Ng KY; Lillehei KO
Cancer Control; 2003; 10(2):138-47. PubMed ID: 12712008
[TBL] [Abstract][Full Text] [Related]
9. Exploitation of immune mechanisms in the treatment of central nervous system cancer.
Pollack IF; Okada H; Chambers WH
Semin Pediatr Neurol; 2000 Jun; 7(2):131-43. PubMed ID: 10914414
[TBL] [Abstract][Full Text] [Related]
10. The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain.
Weller M; Fontana A
Brain Res Brain Res Rev; 1995 Sep; 21(2):128-51. PubMed ID: 8866671
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma.
Deng S; Zhu S; Qiao Y; Liu YJ; Chen W; Zhao G; Chen J
Protein Cell; 2014 Dec; 5(12):899-911. PubMed ID: 25411122
[TBL] [Abstract][Full Text] [Related]
12. From glioma gloom to immune bloom: unveiling novel immunotherapeutic paradigms-a review.
Regmi M; Wang Y; Liu W; Dai Y; Liu S; Ma K; Lin G; Yang J; Liu H; Wu J; Yang C
J Exp Clin Cancer Res; 2024 Feb; 43(1):47. PubMed ID: 38342925
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
